Filing Details
- Accession Number:
- 0001209191-20-010550
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-19 16:37:34
- Reporting Period:
- 2020-02-17
- Accepted Time:
- 2020-02-19 16:37:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1406338 | Amit Sachdev | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Patient Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-17 | 3,262 | $241.50 | 42,936 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2020-02-18 | 720 | $242.04 | 42,216 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-18 | 1,260 | $242.85 | 40,956 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-18 | 540 | $244.08 | 40,416 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-18 | 720 | $245.15 | 39,696 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-18 | 249 | $245.82 | 39,447 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 16,190 | Indirect | Held in Trust |
| Common Stock | 882 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $242.04 (range $241.43 to $242.40).
- Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $242.85 (range $242.45 to $243.32).
- Open market sales reported on this line occurred at a weighted average price of $244.08 (range $243.52 to $244.43).
- Open market sales reported on this line occurred at a weighted average price of $245.15 (range $244.77 to $245.51).
- Open market sales reported on this line occurred at a weighted average price of $245.82 (range $245.82 to $245.85).
Billionaire Hedge Funds
